Literature DB >> 30154149

Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.

Noémie Braekeveldt1, Kristoffer von Stedingk2,3, Susanne Fransson4, Angela Martinez-Monleon4, David Lindgren1, Håkan Axelson1, Fredrik Levander5, Jakob Willforss5, Karin Hansson5, Ingrid Øra6, Torbjörn Backman7, Anna Börjesson7, Siv Beckman1, Javanshir Esfandyari1, Ana P Berbegall8, Rosa Noguera8, Jenny Karlsson9, Jan Koster3, Tommy Martinsson4, David Gisselsson9,10, Sven Påhlman1, Daniel Bexell11,10.   

Abstract

Patient-derived xenografts (PDX) and the Avatar, a single PDX mirroring an individual patient, are emerging tools in preclinical cancer research. However, the consequences of intratumor heterogeneity for PDX modeling of biomarkers, target identification, and treatment decisions remain underexplored. In this study, we undertook serial passaging and comprehensive molecular analysis of neuroblastoma orthotopic PDXs, which revealed strong intrinsic genetic, transcriptional, and phenotypic stability for more than 2 years. The PDXs showed preserved neuroblastoma-associated gene signatures that correlated with poor clinical outcome in a large cohort of patients with neuroblastoma. Furthermore, we captured spatial intratumor heterogeneity using ten PDXs from a single high-risk patient tumor. We observed diverse growth rates, transcriptional, proteomic, and phosphoproteomic profiles. PDX-derived transcriptional profiles were associated with diverse clinical characteristics in patients with high-risk neuroblastoma. These data suggest that high-risk neuroblastoma contains elements of both temporal stability and spatial intratumor heterogeneity, the latter of which complicates clinical translation of personalized PDX-Avatar studies into preclinical cancer research.Significance: These findings underpin the complexity of PDX modeling as a means to advance translational applications against neuroblastoma. Cancer Res; 78(20); 5958-69. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30154149     DOI: 10.1158/0008-5472.CAN-18-0527

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.

Authors:  Yungchang Chen; Ran Zhang; Li Wang; Arlene M Correa; Apar Pataer; Yi Xu; Xiaoshan Zhang; Chenghui Ren; Shuhong Wu; Qing H Meng; Junya Fujimoto; Vanessa B Jensen; Mara B Antonoff; Wayne L Hofstetter; Reza J Mehran; George Pisimisis; David C Rice; Boris Sepesi; Ara A Vaporciyan; Garrett L Walsh; Stephen G Swisher; Jack A Roth; John V Heymach; Bingliang Fang
Journal:  Cancer       Date:  2019-07-09       Impact factor: 6.860

2.  LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy.

Authors:  Pavlos Missios; Edroaldo Lummertz da Rocha; Daniel S Pearson; Julia Philipp; Maria M Aleman; Mehdi Pirouz; Dorian Farache; Joseph W Franses; Caroline Kubaczka; Kaloyan M Tsanov; Deepak K Jha; Brian Pepe-Mooney; John T Powers; Richard I Gregory; Amy Sy Lee; Daniel Dominguez; David T Ting; George Q Daley
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

3.  Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.

Authors:  Sofie Mohlin; Karin Hansson; Katarzyna Radke; Sonia Martinez; Carmen Blanco-Apiricio; Cristian Garcia-Ruiz; Charlotte Welinder; Javanshir Esfandyari; Michael O'Neill; Joaquin Pastor; Kristoffer von Stedingk; Daniel Bexell
Journal:  EMBO Mol Med       Date:  2019-07-16       Impact factor: 12.137

4.  Multidimensional intratumour heterogeneity in neuroblastoma.

Authors:  Kristoffer von Stedingk; David Gisselsson; Daniel Bexell
Journal:  Oncotarget       Date:  2019-01-01

5.  Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy.

Authors:  Alvin Kamili; Andrew J Gifford; Nancy Li; Chelsea Mayoh; Shu-Oi Chow; Timothy W Failes; Georgina L Eden; Roxanne Cadiz; Jinhan Xie; Robyn E Lukeis; Murray D Norris; Michelle Haber; Geoffrey B McCowage; Greg M Arndt; Toby N Trahair; Jamie I Fletcher
Journal:  Br J Cancer       Date:  2020-01-10       Impact factor: 7.640

6.  Anti-tumor effects of rigosertib in high-risk neuroblastoma.

Authors:  Katarzyna Radke; Karin Hansson; Jonas Sjölund; Magdalena Wolska; Jenny Karlsson; Javanshir Esfandyari; Kristian Pietras; Kristina Aaltonen; David Gisselsson; Daniel Bexell
Journal:  Transl Oncol       Date:  2021-06-09       Impact factor: 4.243

7.  Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.

Authors:  Sarah Meneceur; Annett Linge; Matthias Meinhardt; Sandra Hering; Steffen Löck; Rebecca Bütof; Dietmar Krex; Gabriele Schackert; Achim Temme; Michael Baumann; Mechthild Krause; Cläre von Neubeck
Journal:  Cancers (Basel)       Date:  2020-04-03       Impact factor: 6.639

8.  Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response.

Authors:  Esther Hee; Meng Kang Wong; Sheng Hui Tan; Zhang'E Choo; Chik Hong Kuick; Sharon Ling; Min Hwee Yong; Sudhanshi Jain; Derrick W Q Lian; Eileen H Q Ng; Yvonne F L Yong; Mee Hiong Ren; Nurfarhanah Syed Sulaiman; Sharon Y Y Low; Yong Wei Chua; Muhammad Fahmy Syed; Tony K H Lim; Shui Yen Soh; Prasad Iyer; Michaela S F Seng; Joyce C M Lam; Enrica E K Tan; Mei Yoke Chan; Ah Moy Tan; Yong Chen; Zhixiong Chen; Kenneth T E Chang; Amos Hong Pheng Loh
Journal:  Cancer Sci       Date:  2020-08-28       Impact factor: 6.716

9.  Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.

Authors:  Alessandra Dondero; Martina Morini; Davide Cangelosi; Katia Mazzocco; Martina Serra; Grazia Maria Spaggiari; Gianluca Rotta; Annalisa Tondo; Franco Locatelli; Aurora Castellano; Francesca Scuderi; Angela Rita Sementa; Alessandra Eva; Massimo Conte; Alberto Garaventa; Cristina Bottino; Roberta Castriconi
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

Review 10.  The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma.

Authors:  Elizabeth R Tucker; Sally George; Paola Angelini; Alejandra Bruna; Louis Chesler
Journal:  J Pers Med       Date:  2021-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.